Ming Tao

Dr. Ming Tao

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2024 in Medicine
Verified
Journal Article
Open access
YCyan chen
yan chen
MLMin Lai
Min Lai
MTMing Tao
Ming Tao
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder. Dementia severity was assessed mainly through cognitive function, psychobehavioral symptoms, and daily living ability. Currently, there are not many drugs that can be selected to treat mild to moderate AD, and the value of drugs remains controversial. Objective: The aim of this study is to quantitatively evaluate the efficacy and safety of cholinesterase inhibitors (ChEIs), memantine, and sodium oligomannate (GV-971) in the treatment of patients with AD. Additionally, molecular docking analysis will be used to investigate the binding affinities of donepezil, galantamine, rivastigmine, and memantine with key receptor proteins associated with AD, including beta-amyloid (Abeta), microtubule-associated protein (MAP), apolipoprotein E4 (APOE4), and Mitofusin-2 (MFN2), to further validate the results of the meta-analysis. Methods: We obtained clinical trials characterized by randomization, placebo control, and double–blinded methodologies concerning ChEIs, memantine, and GV-971. Statistical analysis was performed using Review Manager Version 5.4 software. Molecular docking was also conducted to evaluate the results. Results: All drugs improved the cognitive function, with the effect value ranging from −1.23 (95% CI −2.17 to −0.30) for 20 mg memantine to −3.29 (95% CI −4.14 to −2.45) for 32 mg galantamine. Although 32 mg galanthamine and GV-971 did not improve the clinicians’ Global Impression of Change scale, other drugs showed significant results compared with placebo. On NPI, only 10 mg of donepezil and 24 mg of galantamine had improvement effects. On ADCS/ADL, only 20 mg memantine and 900 mg GV-971 had no significant difference from the placebo. Donepezil 5 mg and GV-971 900 mg did not increase the drug withdrawal rates due to various reasons or adverse reactions when compared to the placebo. Donepezil demonstrated superior binding to the protein and exhibited greater efficacy compared to other drugs. Conclusion: ChEIs, memantine, and GV-971 all can slow the progression of AD but have different effects on respective assessments. Donepezil and GV-971 were relatively well tolerated.

23 July 2025 in Asian Journal of Psychiatry
Verified
Journal Article
Closed access
CWChu Wang
Chu Wang
ZWZhengyi Wang
Zhengyi Wang
MHMaría Trinidad Herrero
María Trinidad Herrero
TXTao Xu
Tao Xu
FCFengfeng Chu
Fengfeng Chu
MTMing Tao
Ming Tao

27 March 2024 in The Journal Of Prevention of Alzheimer's Disease
Verified
Journal Article
Open access
CWC. Wang
C. Wang
WYW. Yu
W. Yu
TXT. Xu
T. Xu
HZH. Zeng
H. Zeng
AGA. González-Cuello
A. González-Cuello
MTMing Tao
Ming Tao
Alzheimer's disease (AD) is a neurodegenerative disorder featured by progressive cognitive decline, which manifests in severe impairment of memory, attention, emotional processing and daily activities, leading to significant disability and social burden. Investigation on Mild Cognitive Impairment (MCI), the prodromal and transitional stage between normal aging and AD, serves as a key in diagnosing and slowing down the progression of AD. Numerous effects have been made up to date, however, the attentional mechanisms under different external emotion stimuli in MCI and AD are still unexplored in deep. To further explore the attentional mechanisms under different external emotion stimuli in both MCI and AD patients. In 51 healthy volunteers (Controls, 24 males and 27 females), 52 MCI (19 males and 33 females), and 47 AD (15 males and 32 females) patients, we administered the visual oddball event-related potentials (ERPs) under three types of external emotional stimuli: Neutral, Happiness and Sadness, in which the components N1, P2, N2 and P3 as well as the abnormal cortical activations corresponding to the significant ERP differences in the three groups were observed. Under all three external emotions, in AD patients, N2 and P3 latencies were significantly prolonged compared to both Controls and MCI. In addition, under Happiness, in MCI, P3 latencies were significantly delayed compared to Controls. Meanwhile, under both Happiness and Sadness, in AD patients, P3 amplitudes were significantly decreased compared to Controls and MCI, respectively. During N2 time window, under Neutral emotion, significant hypoactivation in the right superior temporal gyrus was found in AD patients compared to Controls, and under Happiness, the activation of the right inferior frontal gyrus was significantly attenuated in MCI compared to Controls. Under Sadness, in AD patients, the activation of the right superior frontal gyrus was significantly decreased compared to MCI. During P3 time window, under both Happiness and Sadness, when AD patients compared to MCI, the significantly attenuated activations were located in the right fusiform gyrus and the right middle occipital gyrus, respectively. Our results demonstrated visual attentional deficits under external emotional stimuli in both MCI and AD patients, highlighting the function of Happiness for early detecting MCI, in which the P3 latency and the hypoactivation of right inferior frontal gyrus during N2 time window can be early signs. The current study sheds further light of attentional mechanisms in MCI and AD patients, and indicates the value of emotional processing in the early detection of cognitive dysfunction.

17 May 2025 in Computer Methods and Programs in Biomedicine
Verified
Journal Article
Closed access
XKXinni Kong
Xinni Kong
YGYaru Guo
Yaru Guo
YOYu Ouyang
Yu Ouyang
WCWenjie Cheng
Wenjie Cheng
MTMing Tao
Ming Tao
HZHong Zeng
Hong Zeng

14 March 2025 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
SHShuning Hong
Shuning Hong
MCMengjiao Chi
Mengjiao Chi
HCHaisi Chen
Haisi Chen
FCFengfeng Chu
Fengfeng Chu
YZYuping Zheng
Yuping Zheng
MTMing Tao
Ming Tao
Objective: We aimed to investigate the metacognition of patients with major depressive disorder (MDD) and its correlation with their condition, as well as explore its diagnostic significance in the early stages of the disease, thereby providing a reference for clinical treatment.Methods: Using a cross-sectional research design, we selected 66 patients diagnosed with MDD and 99 healthy controls for a mental rotation task; we examined their metacognitive performance using a post-decisional confidence assessment paradigm. We evaluated various aspects, including their performance on first-order tasks (d’), metacognitive bias (average confidence), metacognitive sensitivity (meta-d’), metacognitive efficiency (the M Ratio).Results: In terms of the first-order task performance (d’), the group with MDD scored significantly lower than the healthy controls (t = -4.274, p < 0.001, respectively). Regarding metacognitive bias(average confidence), metacognitive sensitivity (meta-d’), and metacognitive efficiency (the M ratio), the group with MDD performed significantly worse than the healthy controls (t = -4.280, p < 0.001; t = -3.540, p < 0.001; t = -2.104, p = 0.039, respectively). In addition, the Hamilton Rating Scale for Depression (HAMD-17) scores of the patients with MDD were significantly negatively correlated with their d’, average confidence levels, meta-d’, and M ratio(r = -0.468, p < 0.001; r = -0.601, p < 0.001;r = -0.457, p < 0.001; r = -0.362, p = 0.003), The average confidence levels of MDD patients are significantly positively correlated with d’, meta-d’, and M ratio. (r = -0.552, p < 0.001; r = 0.738, p < 0.001;r =0.273, p =0.02).Conclusion: The metacognitive abilities of patients with MDD were significantly impaired, and the degree of metacognitive impairment was related to the severity of clinical depressive symptoms. Moreover, the impairment of their metacognitive abilities was correlated with negative metacognitive bias.Clinical Trial Registration: https://www.chictr.org.cn, identifier ChiCTR2400091242

9 August 2024 in IEEE Journal of Biomedical and Health Informatics
Verified
Journal Article
Closed access
HZHong Zeng
Hong Zeng
YZYue Zhao
Yue Zhao
Fabio BabiloniFabio Babiloni
Fabio Babiloni
MTMing Tao
Ming Tao
Wanzeng KongWanzeng Kong
Wanzeng Kong
GDGuojun Dai
Guojun Dai
In electroencephalogram (EEG) cognitive recognition research, the combined use of artificial neural networks (ANNs) and spiking neural networks (SNNs) plays an important role to realize different categories of recognition tasks. However, most of the existing studies focus on the unidirectional interaction between an ANN and a SNN, which may be overly dependent on the performance of ANNs or SNNs. Inspired by the symbiosis phenomenon in nature, in this study, we propose a general DNA-like Hybrid Symbiosis (DNA-HS) framework, which enables mutual learning between the ANN and the SNN generated by this ANN through parametric genetic algorithm and bidirectional interaction mechanism to enhance the optimization ability of the model parameters, resulting in a significant improvement of the performance of the DNA-HS framework in all aspects. By comparing with seven typical EEG cognitive recognition models, the performance of the seven hybrid network frameworks constructed using this method on different EEG-based cognitive recognition tasks are all improved to different degrees, verifying the effectiveness of the proposed method. This unified hybrid network framework similar to the DNA structure is expected to open up a new approach and form a new research paradigm for EEG-based cognitive recognition task.